Nivolumab-associated acute glomerulonephritis: a case report and literature review

BACKGROUND: Immune checkpoint inhibitors are changing the landscape of oncology treatment as they are significantly improving treatment for multiple malignancies. Nivolumab, an anti-programmed death 1 antibody, is a US Food and Drug Administration-approved treatment for melanoma, non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Kyungsuk, Zeng, Xu, Bilusic, Marijo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120473/
https://www.ncbi.nlm.nih.gov/pubmed/27876011
http://dx.doi.org/10.1186/s12882-016-0408-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120473/
https://www.ncbi.nlm.nih.gov/pubmed/27876011
http://dx.doi.org/10.1186/s12882-016-0408-2

Ejemplares similares